Tidal Investments LLC decreased its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 46.8% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 38,334 shares of the biotechnology company's stock after selling 33,710 shares during the quarter. Tidal Investments LLC's holdings in ADMA Biologics were worth $766,000 at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. Quest Partners LLC purchased a new position in shares of ADMA Biologics during the second quarter valued at about $29,000. Hollencrest Capital Management bought a new position in ADMA Biologics during the third quarter valued at approximately $30,000. Larson Financial Group LLC purchased a new position in ADMA Biologics during the 3rd quarter valued at approximately $31,000. National Bank of Canada FI bought a new stake in ADMA Biologics in the 3rd quarter worth approximately $35,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in shares of ADMA Biologics during the 3rd quarter worth approximately $62,000. 75.68% of the stock is owned by hedge funds and other institutional investors.
ADMA Biologics Trading Down 2.8 %
ADMA traded down $0.50 during trading hours on Friday, reaching $17.40. 6,941,298 shares of the company's stock traded hands, compared to its average volume of 3,573,030. The firm has a 50-day moving average price of $18.92 and a 200 day moving average price of $16.30. The firm has a market capitalization of $4.11 billion, a PE ratio of 62.14 and a beta of 0.70. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 52-week low of $4.07 and a 52-week high of $23.64.
ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm had revenue of $119.84 million for the quarter, compared to analysts' expectations of $107.25 million. During the same period in the prior year, the business posted $0.01 earnings per share. As a group, sell-side analysts predict that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of equities analysts have commented on the stock. HC Wainwright lifted their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday, November 8th. Cantor Fitzgerald restated an "overweight" rating and set a $20.00 price objective on shares of ADMA Biologics in a research report on Friday, September 20th. Finally, Raymond James lifted their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a report on Friday, November 8th.
View Our Latest Report on ADMA
Insider Activity at ADMA Biologics
In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the firm's stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares of the company's stock, valued at approximately $4,218,007.95. This trade represents a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.70% of the stock is owned by company insiders.
About ADMA Biologics
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Featured Articles
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
